SESSION 11: HODGKIN LYMPHOMA
CIRCULATING TUMOR DNA IS A PROGNOSTIC BIOMARKER IN CLASSIC HODGKIN LYMPHOMA abstract
V. Spina, M. C. Pirosa, A. Bruscaggin, A. Condoluci, et al.
The study authors conclude that ctDNA load is a strong, independent prognostic factor in cHL. Next studies should aim at the external validation of this biomarker and its integration with radiomics.
RELAPSES IN INTERIM PET NEGATIVE LIMITED STAGE HODGKIN LYMPHOMA PATIENTS RECEIVING ABVD WITH OR WITHOUT RADIOTHERAPY–ANALYSIS OF EORTC/FIL/LYSA H10 AND UK NCRI RAPID TRIALS abstract
I. Aurer, A. Neven, V. Fiaccadori, N. Counsell, et al.
The study authors conclude that the independent validation with RAPID and the combined analysis confirm the H10 finding that omitting RT in iPET neg. patients treated with C results in an increase in early relapses. Moreover, in both studies, relapses after C were more frequently confined to initially involved areas alone.
CALGB 50801 (ALLIANCE): PET ADAPTED THERAPY IN BULKY STAGE I/II CLASSIC HODGKIN LYMPHOMA (CHL). abstract
A. S. LaCasce, T. Dockter, A. Ruppert, L. Kostakoglu, et al.
The study authors conclude that excellent progression-free survival outcomes were observed in all patients using a PET-adapted approach that allowed omission of RT in 78% of patients. In addition, PET2+ patients treated with escalation to BEACOPP and consolidative RT did not have inferior outcomes.
NEW PROGNOSTIC SCORE INCORPORATING MTV PREDICTS TREATMENT FAILURE IN ADVANCED HODGKIN LYMPHOMA abstract
S. F. Barrington, A. A. Kirkwood, L. C. Pike, C. Guezennec, et al.
The study authors conclude that this new prognostic score can be used to identify patients in whom a more intensive initial therapy than ABVD would be most useful, whilst avoiding escalation for those with a high chance of cure with ABVD alone. As the score is continuous, the cut point could be changed depending on the proposed therapy and the risk/reward balance for over/under treatment.
NIVOLUMAB FOR RELAPSED OR REFRACTORY (R/R) CLASSICAL HODGKIN LYMPHOMA (CHL) AFTER AUTOLOGOUS TRANSPLANTATION: 5-YEAR OVERALL SURVIVAL FROM THE PHASE 2 CHECKMATE 205 STUDY abstract
S. M. Ansell, P. J. Bröckelmann, G. von Keudell, H. J. Lee, et al.
The study authors conclude that their 5-y analysis of CheckMate 205 cohorts ABC demonstrated a favorable overall survival and confirms the efficacy and safety of NIVO for patients with cHL who progressed or relapsed after auto-HCT. The safety profile is similar to previous reports. For the authors, it appears feasible to stop NIVO after 1 y of CR and re-initiate tx upon disease progression.
CAMIDANLUMAB TESIRINE EFFICACY AND SAFETY IN AN OPEN-LABEL, MULTICENTER, PHASE 2 STUDY OF PATIENTS (PTS) WITH RELAPSED OR REFRACTORY CLASSICAL HODGKIN LYMPHOMA (R/R CHL) abstract
P. L. Zinzani, C. Carlo-Stella, M. Hamadani, A. F. Herrera, et al.
The study authors conclude that Cami demonstrated high ORR in heavily pretreated R/R cHL after the failure of BV and PD-1 blockade, with encouraging DOR. Safety remains consistent with prior findings. Updated results for the total population (N = 117) are presented.